Avid Bioservices, Inc.

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte

Pfizer Inc. 's commitment of an additional $600m to its corporate venture capital fund includes a plan to spend 25% on neuroscience investments – a curious move considering the company's decision at t

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Neurotrope Inc. has appointed Charles Ryan CEO, effective Feb. 15, 2018, following the resignation of Susanne Wilke. Ryan served as senior vice president and chief intellectual property counsel